TriangleNCT03599713 · CITED IN SOURCE DOCUMENTS
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2025-08-05
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Objective Response Rate (ORR)
Duration of Response (DOR)
Disease Control Rate (DCR)
Progression-free Survival (PFS)
Overall Survival
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
First-dose Cmax of Retifanlimab
First-dose Cmin of Retifanlimab
First-dose AUC0-t of Retifanlimab
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Signed informed consent. * Diagnosis of MCC with distant metastatic disease or recurrent, advanced locoregional disease not amenable to surgery or radiation * Eastern Cooperative Oncology Group performance status of 0 to 1. * Measurable disease according to RECIST v1.1. * Availability of tumor tissue (fresh or archival) for central pathology review. * Willingness to avoid pregnancy or fathering children based on protocol-defined criteria. Exclusion Criteria: * Prior systemic therapy for MCC, including chemotherapy and prior PD-1 or PD-L1-directed therapy. * Treatment with anticancer drugs or participation in another interventional clinical study within 21 days before the first administration of study drug. * Has not recovered to ≤ Grade 1 or baseline from toxic effects of prior therapy (with the exceptions for anemia not requiring transfusion support and any grade of alopecia) and/or complications from prior surgical intervention within 7 days before starting study treatment. * Radiation therapy administered within 2 weeks of first dose of study treatment or radiation therapy to the thoracic region that is \> 30 Gy within 6 months of the first dose of study treatment. * Known central nervous system (CNS) metastases and/or carcinomatous meningitis. * History of second malignancy within 3 years (with exceptions). * Laboratory values outside the protocol-defined range at screening. * Clinically significant pulmonary, cardiac, gastrointestinal or autoimmune disorders. * Active bacterial, fungal, or viral infections, including hepatitis A, B, and C. * Receipt of a live vaccine within 28 days of planned start of study therapy. * Current use of protocol-defined prohibited medication. * Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (eg, antihistamines and corticosteroids). * Inability or unlikely, in the opinion of the investigator, to comply with the Protocol requirements. * Participant who is pregnant or breastfeeding.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- intervention Names
- Drug: Retifanlimab
- label
- Retifanlimab: Chemotherapy: Naïve
- type
- EXPERIMENTAL
- intervention Names
- Drug: Retifanlimab
- label
- Retifanlimab: Chemotherapy: Refractory
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Retifanlimab: Chemotherapy: Naïve
- Retifanlimab: Chemotherapy: Refractory
- description
- INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks
- name
- Retifanlimab
- other Names
- MGA012
- INCMGA00012
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 107
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- ORR was defined as the percentage of participants with a confirmed overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1), as determined by Independent Central Radiographic Review (ICR), at any post-Baseline visit until the first progressive disease (PD) or new anti-cancer therapy. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.
- measure
- Objective Response Rate (ORR)
- time Frame
- up to 26.8 months
- secondary Outcomes
- description
- DOR was defined as the time from an initial objective response (CR or PR) per RECIST v1.1 until PD, or death due to any cause, as determined by ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. A Kaplan-Meier estimate (estimated median) of the distribution function is reported.
- measure
- Duration of Response (DOR)
- time Frame
- up to 55.3 months
- description
- DCR was defined as the percentage of participants with a confirmed overall response (CR and PR) or stable disease (SD) (non-CR/non-PD) lasting at least 6 months from the start of treatment, until the first PD or new anti-cancer therapy, per RECIST v1.1 as determined by ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.
- measure
- Disease Control Rate (DCR)
- time Frame
- up to 57.1 months
- description
- According to RESIST v1.1, PFS was defined the time from the start of therapy until disease progression, or death due to any cause, as determined by ICR. Evaluation of target lesions: PD: ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. The sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered PD). Evaluation of non-target lesions: PD: Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered PD).
- measure
- Progression-free Survival (PFS)
- time Frame
- up to 57.1 months
- description
- Overall survival was defined as the time in months between the first dose date (Day 1) and the date of death due to any cause.
- measure
- Overall Survival
- time Frame
- up to 60.4 months
- description
- An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as either an AE reported for the first time or a worsening of a pre-existing event after the first dose of study drug until 90 days after the last dose of study drug. An AE with onset on/after starting a new anticancer therapy was not summarized as a TEAE.
- measure
- Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
- time Frame
- up to 846 days (up to approximately 2.3 years)
- description
- Cmax was defined as the maximum observed plasma concentration.
- measure
- First-dose Cmax of Retifanlimab
- time Frame
- preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1
- description
- Cmin was defined as the minimum observed plasma concentration over the dose interval.
- measure
- First-dose Cmin of Retifanlimab
- time Frame
- preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1
- description
- AUC0-t was defined as the area under the plasma concentration-time curve from time zero to time t.
- measure
- First-dose AUC0-t of Retifanlimab
- time Frame
- preinfusion, 10 minutes postinfusion (± 10 minutes), and 4 hours postinfusion (± 10 minutes) on Day 1 of Cycle 1
Full study description
- brief Summary
- The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
Source references
- references
- citation
- Grignani G, Rutkowski P, Lebbe C, Guida M, Gaudy-Marqueste C, Spagnolo F, Burgess M, Morano F, Montaudie H, Depenni R, Spada F, Yeung CCS, Pulini J, Cornfeld M, Tian C, Bhatia S. Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201). J Immunother Cancer. 2025 Aug 11;13(8):e012478. doi: 10.1136/jitc-2025-012478.
- pmid
- 40796223
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-7bab4c536db3a98a2354
- requested nct id
- NCT03599713
- primary nct id
- NCT03599713
- source kind
- fda_spl_label
- source record id
- 91ad9008-46bd-4619-946f-75174fceaf56
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- db6b41e52c0711c0fa99e0a095710039b9c9dbe1c8b59927f57ba3d4d2a78a32
- payload
- application numbers
- BLA761334
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-7bab4c536db3a98a2354
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03599713
- occurrences
- context exact
- able. Figure 1: Kaplan-Meier Curves for PFS in POD1UM-303/InterAACT 2 14.2 Merkel Cell Carcinoma (MCC) The efficacy of ZYNYZ was evaluated in study POD1UM-201 (NCT03599713), an open-label, multiregional, single-arm study in 101 patients with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy
- end
- 6638
- exact text
- NCT03599713
- start
- 6627
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/35/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 91ad9008-46bd-4619-946f-75174fceaf56
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- d4379b21fc6d1d18b448e7457d01445e83effbbe42bfd83281bfd9848e275c17
- spl effective time
- 20260518
- spl set id
- 109648d0-d30a-42fc-8273-39cb1540a751
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-db1f58cf274e9712b4b4
- requested nct id
- NCT03599713
- primary nct id
- NCT03599713
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- ac8ae422bc2992c20116b41966d5ffee0dabf3374bc21b23e9633e4d90cbc9d7
- payload sha256
- 9671517b3e0c8b9bbb278988e26160d635b04b9e3341b5a5f2c1ea928b3f6d77
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-db1f58cf274e9712b4b4
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03599713
- occurrences
- context exact
- ">Evidence (retifanlimab):</p> <div class="pdq-content-list"><ol id="_443"><li>Retifanlimab was evaluated in a phase II trial (<a href="/clinicaltrials/NCT03599713">POD1UM-201</a> [NCT03599713]), published in abstract form, of 101 patients with previously untreated advanced MCC. Patients received 500mg intravenously (IV)
- end
- 136745
- exact text
- NCT03599713
- start
- 136734
- context exact
- > <div class="pdq-content-list"><ol id="_443"><li>Retifanlimab was evaluated in a phase II trial (<a href="/clinicaltrials/NCT03599713">POD1UM-201</a> [NCT03599713]), published in abstract form, of 101 patients with previously untreated advanced MCC. Patients received 500mg intravenously (IV) every 4 weeks.[<a href="#cit
- end
- 136774
- exact text
- NCT03599713
- start
- 136763
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/6d24cad24009441653.html
- source file sha256
- ac8ae422bc2992c20116b41966d5ffee0dabf3374bc21b23e9633e4d90cbc9d7
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:22:16.034632+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- fb3dd43b1ff413d1c278ffbcdf052df5e5999c76f342bd845812469fa82bba1a
- source title
- Merkel Cell Carcinoma Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 9, 2025
- datetime
- 2025-05-09T12:00:00Z
- display
- May 9, 2025
Preserved source evidence · Not medical advice